448 results on '"Hertz, Daniel L."'
Search Results
2. Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity
3. Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US
4. Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226
5. Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
6. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy
7. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations
8. Evolution of predictive risk factor analysis for chemotherapy-related toxicity
9. Chemotherapy-Induced Peripheral Neuropathy
10. Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms
11. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
12. Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer
13. Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel
14. Strategies for DPYD Testing Prior to Fluoropyrimidine Chemotherapy in the United States
15. Recommendations for pharmacogenetic testing in clinical practice guidelines in the US
16. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
17. Predisposing Factors for the Development of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
18. Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912)
19. Chemotherapy-Induced Peripheral Neuropathy
20. Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms
21. Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation
22. Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability
23. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
24. Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity.
25. Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study
26. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226
27. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy
28. Risk of Toxicity from Topical 5‐Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles
29. Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy
30. Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221
31. Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
32. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study
33. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy
34. Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications
35. Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy
36. Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy.
37. Risk of Toxicity From Topical 5‐Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles.
38. Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer
39. Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221
40. Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy
41. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
42. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
43. Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy
44. Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines
45. Improvement Initiative to Develop and Implement a Tool for Detecting Drug-Drug Interactions During Oncology Clinical Trial Enrollment Eligibility Screening
46. Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines who are SuspectedDPYDVariant Carriers Based on a Genetic Data Repository
47. Pharmacogenetic Predictors of Response
48. Supplementary Table 2 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
49. Supplementary Table 4 from Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity
50. Supplementary Figure 3: VAC14 Heterozygous Mice are Sensitive to Nociceptive Stimuli from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.